Expertise in
31
conditions

Dr. Tahseen Mozaffar

Neurology
UC Irvine Medical Center
200 S Manchester Ave Ste 110, 
Orange, CA 
Offers Telehealth
Expertise in
31
conditions
UC Irvine Medical Center
200 S Manchester Ave Ste 110, 
Orange, CA 

Overview

Dr. Tahseen Mozaffar is a Professor of Neurology, Orthopaedic Surgery and Pathology and Laboratory Medicine at University of California, Irvine. He is the Director of the UC Irvine-MDA ALS and Neuromuscular Center and the Director of the Division of Neuromuscular Diseases. Dr. Mozaffar serves as chair of one of the biomedical committees and the institutional liaison for Trials Innovation Hub for the Center for Translational Sciences Award (CTSA) at University of California, Irvine. He is the Principal Investigator for UCI-NEXT, the NeuroNEXT award to the University of California, Irvine, one of 25 such NeuroNEXT sites funded by the NINDS/NIH.

.

Dr. Mozaffar is highly rated in 31 conditions, according to our data. His top areas of expertise are Pompe Disease, Inclusion Body Myositis, Myositis, Myasthenia Gravis, and Thymectomy.

His clinical research consists of co-authoring 158 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency

Neurology Residency, Barnes Hospital, St. Louis

Specialties

Neurology

Licenses

Psychiatry & Neurology in CA

Board Certifications

Board Certification In Neurology, 1996-2026
Board Certification In Neuromuscular Medicine, 2008-2028
Board Certification In Clinical Neuromuscular Pathology, 2015 - 2025

Hospital Affiliations

UCI Medical Center

Languages Spoken

English

Gender

Male

Awards

Best Doctors, 2015-2021
Top Doctors:LA Area Castle Connolly, 2013

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UC Irvine Medical Center
200 S Manchester Ave Ste 110, Orange, CA 92868
Other Locations
UCI Health
101 The City Dr S, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease
A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: MN-166
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1, Followed by an Open-Label Extension
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1, Followed by an Open-Label Extension
Enrollment Status: Completed
Publish Date: April 25, 2025
Intervention Type: Drug
Study Drug: Pitolisant
Study Phase: Phase 2
Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Drug: Topiramate
Study Phase: Phase 2
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological
Study Drugs: HYQVIA, Intravenous Immunoglobulin G
Study Phase: Phase 3
Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Other, Drug
Study Phase: Phase 2
Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: November 29, 2022
Intervention Type: Drug
Study Drug: Memantine
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
Fluid Biomarkers With Deep Phenotyping in Patients With ALS
Fluid Biomarkers With Deep Phenotyping in Patients With ALS
Enrollment Status: Completed
Publish Date: December 16, 2021
A Three-Month, Open-Label, Randomized, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 Versus Myozyme®/Lumizyme® in Patients With Late-Onset GSD-II (Pompe Disease) Followed by Open-Label Treatment With VAL-1221 in All Patients
A Three-Month, Open-Label, Randomized, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 Versus Myozyme®/Lumizyme® in Patients With Late-Onset GSD-II (Pompe Disease) Followed by Open-Label Treatment With VAL-1221 in All Patients
Enrollment Status: Terminated
Publish Date: June 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices
Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices
Enrollment Status: Completed
Publish Date: February 25, 2019
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
Enrollment Status: Terminated
Publish Date: June 14, 2018
Intervention Type: Drug
Study Phase: Phase 3
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
Enrollment Status: Completed
Publish Date: April 27, 2018
View 15 Less Clinical Trials

158 Total Publications

The Mythology of Polymyositis.
The Mythology of Polymyositis.
Journal: Rheumatic diseases clinics of North America
Published: October 29, 2025
Similar Doctors
Namita Goyal
Expertise in
19
conditions
Dr. Namita Goyal
Neurology
Expertise in
19
conditions
Dr. Namita Goyal
Neurology

UC Irvine Medical Center

200 S Manchester Ave Ste 110, 
Orange, CA 
 (1.0 miles away)
714-456-2332
Languages Spoken:
English
See accepted insurances

Dr. Namita Goyal is a UCI Health neurologist with board certifications in neurology, electrodiagnostic medicine and neuromuscular medicine. Dr. Goyal is highly rated in 19 conditions, according to our data. Her top areas of expertise are Inclusion Body Myositis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Myositis, and Primary Lateral Sclerosis.

Expertise in
24
conditions
Dr. Daniela Bota
Neurology
Expertise in
24
conditions
Dr. Daniela Bota
Neurology

UCI Health

101 The City Dr S, 
Orange, CA 
 (0.2 miles away)
714-456-8000
Languages Spoken:
English
See accepted insurances

Daniela Bota is a Neurologist in Orange, California. Dr. Bota is highly rated in 24 conditions, according to our data. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Expertise in
33
conditions
Dr. Daniel W. Shrey
Neurology | Pediatric Neurology
Expertise in
33
conditions
Dr. Daniel W. Shrey
Neurology | Pediatric Neurology
1201 West La Veta Avenue, 
Orange, CA 
 (1.7 miles away)
888-770-2462
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Shrey is a Neurologist and a Pediatric Neurologist in Orange, California. Dr. Shrey is highly rated in 33 conditions, according to our data. His top areas of expertise are West Syndrome, Spasmus Nutans, Lennox-Gastaut Syndrome (LGS), and Epilepsy. Dr. Shrey is currently accepting new patients.

Frequently Asked Questions about Dr. Tahseen Mozaffar

How do I make an appointment with Dr. Tahseen Mozaffar?

You can book an appointment with Dr. Tahseen Mozaffar by calling their office at 714-456-2332. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tahseen Mozaffar a top-rated expert for Pompe Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tahseen Mozaffar is classified as an Elite expert for Pompe Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tahseen Mozaffar specialize in?

While Dr. Tahseen Mozaffar is a Neurology, they have specific expertise in Pompe Disease, Inclusion Body Myositis, and Myositis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Tahseen Mozaffar participate in research or clinical trials?

Yes. Dr. Tahseen Mozaffar has published 158 articles and abstracts on conditions like Pompe Disease. You can view a list of Dr. Tahseen Mozaffar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tahseen Mozaffar accept my insurance?

Dr. Tahseen Mozaffar accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 714-456-2332 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mozaffar's expertise for a condition
ConditionClose
View All 20 Advanced Conditions
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile